Bone Biologics highlights 2025 milestones including $5M offering, 24-month shelf life, Nasdaq compliance

Bone Biologics Corp

Extended validated shelf life of rhNELL-1 protein product candidate to 24 months (prior 12/18 months).
Completed $5M registered public offering in Q2 2025 to fund clinical development and IP initiatives.
Regained Nasdaq minimum bid price compliance in June 2025, maintaining public market access.
Filed U.S. patent application for recombinant human NELL-1 bone regeneration technology.
Expects to complete patient enrollment in NB1 first-in-human clinical trial during 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.